Suspension of trading
Acorda Therapeutics Stock OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 13/08/24 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 07/08/24 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| 1 week | -10.00% | ||
| 1 month | -87.85% | ||
| 3 months | -98.41% | ||
| 6 months | -99.90% | ||
| Current year | -99.91% |
| 1 week | 0 |  | 0.02 |
| 1 month | 0 | | 0.15 |
| 3 years | 0 | | 99.8 |
| 5 years | 0 | | 535.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Ali
COO | Chief Operating Officer | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -10.00% | -99.92% | -99.98% | 16.77K | |
| +4.35% | +16.60% | +58.11% | +95.21% | 62.53B | |
| +2.83% | -3.48% | +24.97% | +67.25% | 52.43B | |
| +0.91% | -0.83% | -17.01% | -13.43% | 23.1B | |
| +0.27% | -3.98% | -11.28% | +350.30% | 21.4B | |
| +0.40% | +3.15% | +27.50% | -9.63% | 21.17B | |
| +0.75% | +1.34% | +32.22% | -25.25% | 17.76B | |
| +9.88% | +23.61% | +222.87% | +385.49% | 15.47B | |
| +2.08% | -1.17% | +13.58% | +564.59% | 14.68B | |
| +1.25% | +2.48% | +51.36% | +179.72% | 14.08B | |
| Average | +2.52% | +4.45% | +30.24% | +149.43% | 26.96B | |
| Weighted average by Cap. | +2.76% | +5.40% | +40.52% | +135.17% |
Employees
-
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
Select your edition
All financial news and data tailored to specific country editions
